JP2015526463A5 - - Google Patents

Download PDF

Info

Publication number
JP2015526463A5
JP2015526463A5 JP2015528010A JP2015528010A JP2015526463A5 JP 2015526463 A5 JP2015526463 A5 JP 2015526463A5 JP 2015528010 A JP2015528010 A JP 2015528010A JP 2015528010 A JP2015528010 A JP 2015528010A JP 2015526463 A5 JP2015526463 A5 JP 2015526463A5
Authority
JP
Japan
Prior art keywords
daptomycin
tocopheryl phosphate
tpm
formulation
lyophilized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015528010A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015526463A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IN2013/000511 external-priority patent/WO2014045296A2/en
Publication of JP2015526463A publication Critical patent/JP2015526463A/ja
Publication of JP2015526463A5 publication Critical patent/JP2015526463A5/ja
Pending legal-status Critical Current

Links

JP2015528010A 2012-08-23 2013-08-22 改善されたダプトマイシン注射用製剤 Pending JP2015526463A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2452/MUM/2012 2012-08-23
IN2452MU2012 2012-08-23
PCT/IN2013/000511 WO2014045296A2 (en) 2012-08-23 2013-08-22 Improved daptomycin injectable formulation

Publications (2)

Publication Number Publication Date
JP2015526463A JP2015526463A (ja) 2015-09-10
JP2015526463A5 true JP2015526463A5 (cg-RX-API-DMAC7.html) 2016-10-06

Family

ID=54187094

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015528010A Pending JP2015526463A (ja) 2012-08-23 2013-08-22 改善されたダプトマイシン注射用製剤

Country Status (12)

Country Link
US (1) US20150216928A1 (cg-RX-API-DMAC7.html)
EP (2) EP2887953B1 (cg-RX-API-DMAC7.html)
JP (1) JP2015526463A (cg-RX-API-DMAC7.html)
AU (2) AU2013319737B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015003198A2 (cg-RX-API-DMAC7.html)
CA (1) CA2881121A1 (cg-RX-API-DMAC7.html)
DK (1) DK2887953T3 (cg-RX-API-DMAC7.html)
ES (1) ES2655215T3 (cg-RX-API-DMAC7.html)
NO (1) NO2887953T3 (cg-RX-API-DMAC7.html)
PT (1) PT2887953T (cg-RX-API-DMAC7.html)
SI (1) SI2887953T1 (cg-RX-API-DMAC7.html)
WO (1) WO2014045296A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4066849B1 (en) 2012-09-11 2025-03-05 Hospira Australia Pty Ltd Daptomycin formulations and uses thereof
ES2946600T3 (es) 2016-10-21 2023-07-21 Xellia Pharmaceuticals Aps Formulaciones líquidas de daptomicina
AU2018322769B2 (en) 2017-08-31 2021-12-02 Xellia Pharmaceuticals Aps Daptomycin formulations
JP2023517926A (ja) 2020-03-12 2023-04-27 バクスター・インターナショナル・インコーポレイテッド ソルビトールとマンニトールの組み合わせを含むダプトマイシン製剤
CN112684043A (zh) * 2020-12-16 2021-04-20 南京健友生化制药股份有限公司 一种达托霉素有关物质的检测方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
FR2657526B1 (fr) * 1990-01-31 1994-10-28 Lvmh Rech Utilisation d'un phosphate d'alpha-tocopherol, ou de l'un de ses derives, pour la preparation de compositions cosmetiques, dermatologiques, ou pharmaceutiques; compositions ainsi obtenues.
CN1069320C (zh) * 1995-10-17 2001-08-08 昭和电工株式会社 高纯度生育酚磷酸酯,其生产方法和含有该化合物的化妆品
JP4088597B2 (ja) * 2004-01-06 2008-05-21 樹男 飯田 内服および注射用組成物とその製法
JP5041279B2 (ja) * 2004-04-22 2012-10-03 株式会社 Mbr 細菌細胞壁骨格成分を含有する製剤
CA2611831C (en) * 2005-06-17 2014-09-16 Vital Health Sciences Pty Ltd. A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
WO2011028850A1 (en) * 2009-09-01 2011-03-10 Northwestern University Delivery of therapeutic agents using oligonucleotide-modified nanoparticles as carriers
WO2011035108A1 (en) * 2009-09-17 2011-03-24 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
CA2781666C (en) * 2009-11-23 2017-02-21 Cubist Pharmaceuticals, Inc. Lipopeptide compositions and related methods
AU2011213557B2 (en) * 2010-02-05 2015-05-07 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
CA2752784A1 (en) * 2010-09-21 2012-03-21 Xellia Pharmaceuticals Aps Daptomycin formulation

Similar Documents

Publication Publication Date Title
JP2015526463A5 (cg-RX-API-DMAC7.html)
HRP20200072T1 (hr) Načini doziranja za spojeve klase ehinokandina
AU2016204371A1 (en) Lyophilised and aqueous anti-CD40 antibody formulations
MX389346B (es) Formulaciones de anticuerpos monoclonales de alta concentración.
EA200901128A1 (ru) Твердый фармацевтический препарат и вакцинная доза
NZ700182A (en) Parenteral formulations for administering macrolide antibiotics
MX340985B (es) Compuestos de n-heteroarilo.
FI3685847T3 (fi) Komplementtiaktiivisuuden modulaattoreita
UA117480C2 (uk) Лікування цукрового діабету за допомогою складу інсуліну тривалої дії
EP4218769A3 (en) Treatment of oculopharyngeal muscular dystrophy by intravenous administration of trehalose
EA201691490A1 (ru) Фармацевтическая композиция, содержащая бринзоламид
MX2015016750A (es) Composicion inmunogenica para uso en terapia.
SI2887953T1 (en) IMPROVED DAPTOMICINE FORMATION FORMULATION
WO2016040814A3 (en) Disulfide polymers and methods of use
MY184630A (en) Tylosin derivatives and method for preparation thereof
RU2017144216A (ru) Антибактериальные композиции
JP2014504613A5 (cg-RX-API-DMAC7.html)
RU2015145451A (ru) Препараты для местного применения, содержащие гиалуроновую кислоту, вербаскозид и глицерофосфоинозитол
WO2014145713A3 (en) Aminoglycoside antibiotics with reduced ototoxicity
CN103211755A (zh) 无菌稳定的阿奇霉素滴眼液的生产方法
UA115333C2 (uk) Склад есмололу для парентерального введення
RU2016101248A (ru) Лиофилизированные препараты бендамустина гидрохлорида
WO2011126327A3 (en) Pharmaceutical composition with controlled-release properties comprising mosapride or levodropropizine, and preparing method thereof
CN104173274A (zh) 复方盐酸消旋山莨菪碱注射液及制备方法
MX2013011767A (es) Composicion farmaceutica solida.